Today: 7 February 2026
Subscribe

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade shares jumped 7.7% to $85.81 Monday, hitting a new 52-week high amid heavy short interest and volatile trading. About 20% of the float was shorted as of mid-December, raising the risk of sharp moves. Chief insurance officer John Peters sold 10,000 shares Jan. 6 at $80 under a pre-set plan. The next earnings report is expected Feb. 24.
12 January 2026
··
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta Therapeutics shares fell 13% to $20.73 Monday after a preliminary update showed weaker-than-expected fourth-quarter sales for its Duchenne gene therapy, Elevidys. The company reported $110.4 million in Elevidys revenue for the quarter, below Wall Street’s $122 million estimate. Sarepta cited a severe flu season and delayed six patient infusions to 2026. Final results are due in late February.
12 January 2026
·
Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch shares fell 17.3% to $103.26 after the company cut its full-year sales growth forecast and lowered its holiday-quarter outlook. The retailer now expects fiscal 2025 net sales growth of at least 6%, down from a prior 6%–7% range, and factored in $90 million in tariff expenses. Investors are watching the ICR Conference this week for further updates on demand and pricing.
12 January 2026
·
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck shares fell 1.1% to $109.27 Monday amid speculation over a possible $28–32 billion acquisition of Revolution Medicines, though no deal has been finalized. The SPDR S&P Biotech ETF dropped 2.1%. Analysts estimate Revolution’s RAS inhibitor drugs could generate over $10 billion in sales by 2035. Merck also faces a potential $2 billion annual revenue hit after U.S. vaccine schedule changes affecting Gardasil and RotaTeq.
12 January 2026
··
Goldman Sachs stock ticks up as Powell probe threat, rate-cap talk keep banks on edge

Goldman Sachs stock ticks up as Powell probe threat, rate-cap talk keep banks on edge

Goldman Sachs shares rose 0.6% to $944.73 in Monday afternoon trading ahead of fourth-quarter earnings due Jan. 15. Markets weighed Trump’s proposed 10% cap on credit-card interest rates and threats to indict Fed Chair Jerome Powell. Traders are focused on Tuesday’s U.S. CPI report and major bank earnings. Goldman’s chief economist now expects Fed rate cuts in June and September.
12 January 2026
···
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
Mastercard stock drops as Trump’s 10% credit-card rate cap plan rattles card-linked names

Mastercard stock drops as Trump’s 10% credit-card rate cap plan rattles card-linked names

Mastercard shares fell 1.7% to $565.93 Monday after President Trump called for a one-year 10% cap on credit card interest rates, sending card stocks lower. Visa dropped 1.7% and American Express slid 4.2%. Analysts said such a cap would need Congressional approval and warned it could hurt lender profits. Separately, Google named Mastercard as an endorser of its new Universal Commerce Protocol for AI-driven shopping.
12 January 2026
·
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
Reddit stock (RDDT) slips as insider selling hits the tape; CPI report is the next test

Reddit stock (RDDT) slips as insider selling hits the tape; CPI report is the next test

Reddit shares fell 1.1% to $241.85 Monday as the S&P 500 and Nasdaq-100 ETFs edged up 0.2%. Wells Fargo raised its price target to $207 but kept an equal-weight rating. SEC filings showed Reddit’s chief legal officer and CFO sold shares under preset trading plans. Daily active users rose 19% to 116 million, with revenue up 68% to $585 million.
12 January 2026
········
First Majestic Silver stock jumps 7% as silver rips to a fresh record — what investors watch next

First Majestic Silver stock jumps 7% as silver rips to a fresh record — what investors watch next

First Majestic Silver shares jumped 7% to $20.24 Monday as silver surged 6.8% to $85.39 an ounce, drawing heavy trading volume. Peer miners also rallied, with Hecla Mining up nearly 9%. Investors await Tuesday’s U.S. inflation data, which could shift rate and metals forecasts. JPMorgan and other banks have delayed expectations for Fed rate cuts into 2026 or later.
12 January 2026
·
1 … 717 718 719 720 721 … 2,716

Stock Market Today

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop